HUM · Humana Inc. · Stock research

Current Thesis

The session the last note flagged as unresolved has printed. The 2026-08-24 close of $386.61 is 2.0% above the 2026-08-21 close of $378.88 and now sits clear of the last 50-day value observed here ($378.33 on 2026-08-12) rather than resting on it. RSI(14) read 64.6 against 52.5 one session earlier. Distance from the adjusted 52-week high of $409.42 narrowed to 5.6% from 7.5%. The shares are up 28.5% over three months; inference, flagged as such: that reading rose more than the single session's 2.0% because the trailing three-month window rolled off early-June sessions, not because of any additional move.

The narrative leg is unchanged and still the reason the name is owned: a margin-over-volume Medicare Advantage reset — exit plans where Star Ratings do not pay, keep the members whose bids work, land on a pre-tax MA margin of "at least 3% in 2028," the phrasing reaffirmed on the 2026-07-29 call and the only forward figure management stands behind.

What this refresh adds is a date. On the Q2 call management said it will hold a virtual investor update on 2026-12-10 to mark to market the 2028 commitments, at which point it will have full visibility into bonus-year 2028 Star Ratings and preliminary 2027 membership expectations. The open question of whether 2027 ever gets quantified now has a named venue — after the 2026-11-06 Q3 call, and roughly fifteen weeks out from the current tape.

Revision flow remains idle. No rating action is recorded after Bernstein's Lance Wilkes maintained Buy at $425 on 2026-08-14. Before that, J.P. Morgan held Neutral and lifted its target to $393 from $316 on 2026-08-10; BofA's Kevin Fischbeck maintained Buy at $500 on 2026-08-07. The consensus across 26 analysts is a $416.43 average and a $415 median against a $280 low and a $513 high, split 11 strong buy, 1 buy, 13 hold, 1 strong sell (stockanalysis.com forecast page, retrieved 2026-08-24). The 08-24 close sits beneath that average and above the two most recent house targets from Morgan Stanley ($370) and J.P. Morgan ($393).

The narrative is maturing. The re-rating wave ran 2026-07-29 through 2026-08-14 and stopped. Since then the coverage is options-scanner posts (Benzinga, 2026-08-10 and 2026-08-17) and a sector-political divestment campaign (2026-08-11, 2026-08-14). Price is making back its post-print highs while the flow that produced them has gone quiet.

Bullish and bearish views on Humana Inc.

The model's bull view on Humana Inc. (HUM), in brief: Q2 cleared both lines and the guide held. The bear view: The GAAP line was cut while the adjusted line was affirmed. Both cases follow in full.

Bull Case

• Q2 cleared both lines and the guide held. Adjusted EPS $7.61 versus $7.22 consensus on revenue $40.888B versus $40.611B; FY2026 adjusted EPS affirmed at "at least $9.00" against $8.94 consensus (2026-07-29 release, Form 8-K and Form 10-Q filed the same day).
• Cost ratio in line while the book grew. Q2 2026 insurance segment GAAP benefit ratio 91.2%, matching the "slightly above 91 percent" framing; FY2026 individual MA membership growth of approximately 25% over 2025 affirmed and the FY benefit-ratio guide of 92.75% held at ±25bps rather than widened (2026-07-29).
• The 2027 rate landed far above the advance notice. CMS finalised an average 2.48% Medicare Advantage payment increase for 2027 against the 0.09% net increase in the January 2026 advance notice, worth roughly $13B a year to plans in contemporaneous coverage (STAT, 2026-04-06).
• The 2028 promise acquired a checkpoint. The 2026-12-10 virtual investor update is management's own commitment to mark to market the 2028 targets with bonus-year 2028 Stars known and preliminary 2027 membership in hand (2026-07-29 call). An open-ended margin pledge now has a dated audit.
• The re-rating was broad, not one house. Between 2026-07-30 and 2026-08-14: Evercore ISI upgrade to Outperform at $480, Piper Sandler upgrade to Overweight at $463 (from Neutral/$254), Guggenheim Buy at $471, UBS Neutral at $405, Barclays Equal-Weight at $407, TD Cowen Hold at $370, Morgan Stanley upgrade to Equal-Weight at $370 (from Underweight/$249), BofA Buy at $500, J.P. Morgan Neutral at $393, Bernstein Buy at $425.
• No insider distribution into the run. The only Humana Form 4 activity located for August 2026 is two director restricted-stock awards of 544 units each on 2026-08-01 at $0 under the annual Director Compensation Program (P.J. Smith, F.J. Crawford). No open-market insider sales are reported (SEC filings, CIK 0000049071).

Bear Case

• The GAAP line was cut while the adjusted line was affirmed. Q2 2026 GAAP EPS $5.73 against adjusted $7.61; FY2026 GAAP EPS revised to "at least $6.52" from "at least $8.36" in the same 2026-07-29 release that held adjusted at "at least $9.00". Underwriting the 2028 margin off adjusted numbers means underwriting a widening reconciliation.
• The exits are large and the recapture rate is management's own estimate. The 2027 plan terminations affect roughly 600,000 members; the just-over-40% recapture figure cited on 2026-07-29 is unverified until enrollment-season disclosures.
• The Star Ratings litigation is unresolved. A Texas district court upheld the CMS downgrade that contemporaneous coverage put at $1B or more of 2026 revenue; the appeal is Fifth Circuit No. 25-11293, with the government's brief dated 2026-03-21 on the Georgetown Litigation Tracker copy and no argument or decision date on the public docket.
• Nothing company-quantified lands for weeks. Humana has published no September 2026 investor-conference participation release as of 2026-08-25, while peer HCA Healthcare published its September slate on 2026-08-20. The only dated company item on the immediate calendar is Humana Community Day on 2026-08-26, a volunteering event with no financial content (Business Wire, 2026-08-04).
• Half the coverage is on the fence at these levels. 13 of 26 analysts sit at hold and the low target is $280 (stockanalysis.com, retrieved 2026-08-24).
• Momentum has re-extended without fresh revision flow. RSI(14) at 64.6 and 5.6% under the 52-week high, eleven calendar days after the last rating action.

Setup & Price Structure

The reference levels, all on the split/dividend-adjusted daily series: 52-week high $409.42; 2026-08-24 close $386.61; 2026-08-21 close $378.88; last 50-day value observed here $378.33 on 2026-08-12; 2026-08-11 close $372.82; 2026-08-05 low $353.69.

The structure since the print is a two-step: an initial run into 2026-08-10, a pullback to the 50-day zone that held at $372.82 on 2026-08-11, a reclaim on 2026-08-12, a drift to $378.88 by 2026-08-21, and a 2.0% session on 2026-08-24 that put price back toward the highs. The August low at $353.69 is the level that defines the leg; $372–$379 is the band where the reclaim was tested and held twice.

On crowding, the observables rather than a verdict: RSI(14) 64.6 in the upper half of its range; the close beneath a $416.43 consensus average with a hold-heavy distribution; two Benzinga options-scanner posts inside eight days (2026-08-10, 2026-08-17) as the only retail-facing coverage of the name in that window; no equity issuance and no open-market insider sales on file for August; and no earnings date inside 30 days, so there is no imminent print to position into. Distance above the last observed 50-day value is roughly 2.2% using the 2026-08-12 reading — an understatement if that average is still rising, which a +28.5% three-month move implies.

Catalyst Calendar (next 30 days)

• 2026-08-26 — Humana Community Day 2026, a nationwide employee volunteering event across Louisville, Central and South Florida, San Antonio and Baton Rouge (Business Wire, 2026-08-04). No financial content; it marks how empty the near calendar is.
• 2026-09-08 to 2026-09-10 — Wells Fargo 21st Annual Healthcare Conference, Boston. Humana participation unannounced as of 2026-08-25. The CFO presented at this venue on 2024-09-04 and 2023-09-06, each preceded by a dedicated release.
• Unscheduled — Fifth Circuit ruling in No. 25-11293. Briefed with no argument date docketed; it can be entered on any session.
• ~2026-09-25 (est.) — CMS releases the 2027 Medicare Advantage and Part D landscape files, the first county-level view of which plans are exited.

Beyond the window but anchoring it: 2027 Star Ratings ~2026-10-08 (est.), Annual Enrollment Period opening 2026-10-15, Q3 earnings 2026-11-06, and the virtual investor update on 2026-12-10.

What Would Change Our Mind

The structure that has to hold is the reclaim band. Two things would break the read as written. First, the August low giving way: a daily close below $372 takes out the 2026-08-11 close of $372.82 and turns the 2026-08-12 reclaim of the 50-day into a failed one, while a weekly close below $353 removes the 2026-08-05 low of $353.69 and ends the leg that began after the 2026-07-29 print. Second, the September window closing empty: the 2026-09-08/10 conference dates passing with no Humana participation release and no intermediate 2027 margin or membership figure would leave the multiple resting on third-party 2028 estimates until 2026-11-06 at the earliest, with the company's own mark-to-market not due until 2026-12-10.

On the fundamental side, the datapoints that would flip the frame are specific: a benefit ratio above the guided 92.75% band at the Q3 print, or that ±25bps width being widened rather than held; a further cut to GAAP EPS guidance while the adjusted line is affirmed again; a 2027 Star Ratings 4-star-plus enrollment share not materially above the roughly 20% recorded on the 2026 ratings; or an appellate decision affirming the district court in No. 25-11293. Any of those attacks the 2028 margin arithmetic directly rather than the chart.

A resumption of revision flow in the other direction — a target cut from one of the houses that raised between 2026-07-30 and 2026-08-14 — would also mark the re-rating as complete rather than pausing.

Correlation Notes

• HUM trades as a CMS-policy beta with UNH, CVS, ELV and CI. On 2026-04-07, the session after the final 2027 rate notice, UnitedHealth rose roughly 11% and Humana roughly 12% with the managed care index up nearly 10% in early trading (24/7 Wall St., Wedbush market note, both 2026-04-07). The ~2026-09-25 landscape files and the ~2026-10-08 Star Ratings are sector-wide prints that move the group together.
• Single-name divergence comes from Stars and the litigation. The Fifth Circuit docket in No. 25-11293 is Humana-specific and carries no read-through to peers.
• The divestment campaign covered on 2026-08-11 and 2026-08-14 targets health insurers as a class; it is an index-level and ETF-flow input, not a Humana disclosure.
• Peer disclosure cadence is a live comparison: HCA Healthcare published its September conference slate on 2026-08-20 while Humana has published none, so the September calendar is currently asymmetric across the sector.